Iyiphi indima enokuthi i-PARP inhibitors ingadlala kwindlela yokwelashwa ngumhlaza webele? Izidakamizwa ezininzi ezibizwa ngokuba yi-PARP inhibitors ziye zafundiswa kutshanje kwonyango lomhlaza wesifuba. Uluhlu luni lwamachiza lwenze ntoni, kwaye yintoni eyona nto inokuthi ibe yinto ebalulekileyo ekulawuleni abantu abanomdlavuza wesibeleko?
Mayelana nePARP kunye ne-DNA Repair
I-PARP isichazizwi se-polymerase (ADP-ribose).
I-PARP yiprotheyini eneendidi ezininzi kwiinkqubo zeselula, ngokugqithiseleyo ekulungiseni i-DNA kunye nokufa kweselungisiwe (apoptosis). Amaseli aphilileyo angasebenzisa i-PARP ukuze azilungiselele aze aphile umjikelezo wabo wokuphila. Kodwa iiselula zomhlaza zingasebenzisa i-PARP ukulungisa umonakalo we-DNA, ngaloo ndlela ukwandisa ukukhula kwawo okungalawulwayo. Amanqamu anjalo angakwazi ukumelana nonyango. Kukho iiproteni ezahlukeneyo zePARP, kwaye ngamnye ngamnye unendima yakhe kwimisebenzi kwiseli.
I-PARP Inhibitors Nonyango lweCarcer Breast
I-PARP inhibitor yisiza esithintela amaprotheni e-PARP ekwenzeni iindima zawo ekulungiseni iiseli zomhlaza zomonakalo. I-Chemotherapy kunye nomsebenzi we- radiation ngokuphula i-DNA yamaseli ukwenzela ukuba bangazalanga. Ezinye iintlobo zesifo somhlaza zisebenzisa i-PARP enzymes ukulungisa umonakalo we-DNA kunye nokuhlaselwa kohlaselo lomhlaza. Izilingo ezininzi zonyango zenziwa ukuba zibone ukuba i-PARP inhibitors, ngokudibanisa nezinye izifo zonyango, ingavimbela iprotheni ye-PARP kumaseli omhlaza okonakaliswe.
Iimiphumo kwiCells Cancer Cells
Ukuba i-PARP inhibitor yongezwa kwonyango lwe-chemotherapy yomhlaza wesifuba, abaphandi banethemba lokuba iiselintshi zomhlaza ezichasene neziyobisi zonyango ziza kuba sisengozini yokulimala kweDNA. Kwezinye iimeko, i-PARP inhibitor ingasetyenziselwa yedwa , kunokuba ihlangane ne-chemo kunye ne-radiation.
Ngona iindaba ezilungileyo kukuba i-PARP inhibitors ayibonakali iyichaphazela iindidi eziqhelekileyo, ezingenayo umdlavuza. Oko kuthetha imiphumo emibini yezigulane kunye nokuphucula ngokukhawuleza kunyango.
Ithemba leCarcer Breast Cancers
I-PARP inhibitors ingaba luncedo kakhulu kwizigulane ezineengxaki zomhlaza wesibeletho. Abantu abane- BRCA1 kunye ne- BRCA2 yokuguquka kwemfuzo basengozini enkulu yokuvelisa umdlavuza webele. Iigciwane ze-BRCA eziphilileyo zivelisa iiprotheni ezinokuthi zithinte ukubunjwa kwe-tumor ( zibizwa ngokuba yi-tumor suppressor genes ), kodwa ziguqula izakhi zegciwane ze-BRCA ezingenamandla okwenza ezi proteins ezilwa namaseli omhlaza. I-PARP inhibitors inokusebenzisa ubunobuthakathaka obunomdlavuza weeseli ezine-BRCA. Enye into enokusetyenziswa ye-PARP inhibitors inokuthi ikhusele umdlavuza webele . Mhlawumbi i-PARP inhibitors iya kuba yonyango lokuthintela abafazi abasengozini enkulu kwaye iza kwenza i-prophylactic mastectomies iphela.
Iindaba ezikhuthazayo zeCancer-Negative Breast Cancers
Izilingo ezimbalwa zeklinikhi ze-PARP inhibitors ziye zathola inzuzo yeklinikhi ngokufaka i-PARP inhibitor kwezinye ionyango kwi-metastatic triple negative cancer . Kule zifundo, i-PARP inhibitors yayinyamezelekile. Ngeli xesha liphela lonyango olujoliswe ekuvunyelwene ngayo ngomhlaza wesisu se-metastatic bevacizumab, kodwa le nkunkuma ayinayo inzuzo eninzi kubantu abanomdlavuza wesifuba kathathu.
Ezinye izinto zokusebenzisa i-PARP Inhibitors
Iziyobisi eziphuhliswe nge-PARP inhibitors zihlolwe kwiintlobo ezininzi zesifo somhlaza: isifuba kunye ne-ovari, uterine, ingqondo kunye ne-pancreatic. Ngo-2015, i-inhibitor ye-PARP yavunywa ukuba yonyango lwezinye iintsholongwane ze-ovari.
Ubaluleka obunokwenzeka be-PARP Inhibitors
Ukongezwa kwe-PARP inhibitors kwi-arsenal yezixhobo ezichasene nomhlaza wesifuba kubonakala kunethemba. I-PARP inhibitors kwandise ukuphumelela kwe-chemotherapy kwiinkomfa zesifo ezinobundlobongela kunye ne-triple-negative, ezingenakongeza ngaphandle kokufaka imiphumo emibi kakhulu. Ezi zi yobisi zibonakala ziphucula umgangatho wobomi kunye nokwandisa ukusinda kwizigulane.
Ukulwa nomhlaza wesifuba kumgangatho we-DNA yayo kubonakala ngathi utshaba lwekamva.
> Imithombo:
> Boerner, J. et al. Iprotheyini Inkcazo ye-DNA yokuLungisa iiprotheni ziCwangcisa ukuphendula kwi-Topoisomerase kunye ne-PARP Inhibitors Kwi-Cancer ye-Breast-negative Cancer. PLos One . 2015. 10 (3: e0119614.
> Ukuza, E., noMnu Robson. I-Poly (ADP-ribose) I-Polymerase Inhibitors kwi-Cancer Breast-negative Cancer. Iphephandaba leMhlaza . 2010. 16 (1): 48-52.
> Dizdar, O., Arslan, C., no K. Altundaq. Intuthuko kwi-PARP Inhibitors kwiNyango yeCanscer Breast. Umbono woLwazi kwi-Pharmacotherapy . 2015. 16 (18): 2751-8.
> Garber, J., noL. Livraghi. I-PARP Inhibitors ekulawulweni kweCarcer Breast: I-Data yangoku kunye neenjongo ezizayo. BMC Medicine . 2015. 13: 188.
> Hiller, D., no-Q. Chu. Isimo samanje sePoly (i-ADP-ribose) i-Polymerase Inhibitors njengeNewvelithi yeArapeutic Agents yeCancer-Negative Breast Cancer. I-International Journal yeCanscer Breast . 2012. 2012: 829315.
> Lee, J. et al. Isifundo se-Phase I / Ib ye-Olaparib neCarboplatin kwi-BRCA1 okanye i-BRCA2 ehambelana nomhlaza okanye i-Ovarian Cancer ne-Biomarker Analyzes. Umbhalo weNational Cancer Institute . 2014. 106 (6): uDju089.
> O'Shaughnessy, J. et al. Iniparib Plus Chemotherapy kwiMetastatic-negative negative Breast Cancer. I-New England Journal of Medicine . 2011. 364 (3): 205-14.
> O'Shaughnessy, J. et al. Umbhalo we-Clinical Oncology . 2014. 32 (34): 3840-7.
> O'Sullivan, C., Chen, A., no S. Kummar. Ukuhambisa kwiZithembiso: Poly ADP Ribose Polymerase Inhibition njenge-AnticancerTect. Umbono okhoyo kwi-Oncology . 2015. 27 (6): 475-81.
> Rios, J., noP. Puhalla. I-PARP Inhibitors kwiCarcer Breast: i-BRCA ne-Beyond. I-Oncology (i-Williston ipaki) . 2011. 25 (11): 1014-25.
> van der Noll, R. et al. Ukhuseleko lwangexesha elide Umsebenzi we-Olaparib Monotherapy Emva kokudibanisa neCarboplatin kunye ne-Paclitaxel kwizigulane ezine-Breast Advanced, i-Ovarian okanye i-Fallopian Tube yomhlaza. IBritish Journal of Cancer . 2015. 113 (3): 396-402.